Belite Bio announces extension of FDA review timeline for tinlarebant NDA
BLTE•The FDA extended its review of Belite Bio’s tinlarebant NDA, setting a new PDUFA date of May 12, 2027. The FDA is expected to communicate labeling and postmarketing requests by April 12, 2027.




